Sun D, Chen G, Chen Y, Qu S, et al. Anti-LAG-3 Antibody LBL-007 Plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial. Clin Cancer Res 2025 Dec 11. doi: 10.1158/1078-0432.CCR-25-2054.
PMID: 41378996